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The incidence of esophageal adenocarcinoma is rising in the 
United States and Europe (1,2). Despite general improvements in 
cancer survival in most countries, patients with esophageal adeno-
carcinoma have a poor prognosis, with fewer than 20% surviving 
for 5 years (3,4). Barrett’s esophagus (BE) is the metaplastic trans-
formation of the native esophageal squamous epithelium into 
columnar epithelium in response to gastroesophageal reflux. 
Patients with BE, a known precursor to esophageal adenocarci-
noma, are estimated to carry a 30- to 60-fold increased risk of 
developing esophageal adenocarcinoma (5).
Endoscopic surveillance of BE is the currently accepted stan-
dard of care and aims to reduce morbidity and mortality through 
early detection of dysplasia or cancer (6,7). The cost-effectiveness 
of surveillance is dependent on the risk of progression of BE to 
cancer (8–10). However, a wide variation in the incidence of 
esophageal adenocarcinoma in BE has been observed, ranging 
from 0% to 3.5% per annum (11,12). Also, it is not currently 
known whether the rate of progression of BE to esophageal adeno-
carcinoma varies with time from diagnosis of BE. Change in risk 
over time has implications regarding both the need for, and the 
frequency of, endoscopic surveillance.
The aim of this study was to examine the risk of adenocarci-
noma or high-grade dysplasia in a large cohort of unselected BE 
patients. The risk of cancer or high-grade dysplasia was examined 
using both the British definition of BE, that is, columnar lined 
epithelium of the esophagus (CLE) and the American definition of 
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 Background Barrett’s esophagus (BE) is a premalignant lesion that predisposes to esophageal adenocarcinoma. However, 
the reported incidence of esophageal adenocarcinoma in patients with BE varies widely. We examined the risk 
of malignant progression in patients with BE using data from the Northern Ireland Barrett’s esophagus Register 
(NIBR), one of the largest population-based registries of BE worldwide, which includes every adult diagnosed 
with BE in Northern Ireland between 1993 and 2005.
 Subjects and  We followed 8522 patients with BE, defined as columnar lined epithelium of the esophagus with or without 
Methods  specialized intestinal metaplasia (SIM), until the end of 2008. Patients with incident adenocarcinomas of the esoph-
agus or gastric cardia or with high-grade dysplasia of the esophagus were identified by matching the NIBR with 
the Northern Ireland Cancer Registry, and deaths were identified by matching with records from the Registrar 
General’s Office. Incidence of cancer outcomes or high-grade dysplasia was calculated as events per 100 person-
years (% per year) of follow-up, and Cox proportional hazard models were used to determine incidence by age, 
sex, length of BE segment, presence of SIM, macroscopic BE, or low-grade dysplasia. All P values were from 
two-sided tests.
 Results After a mean of 7.0 years of follow-up, 79 patients were diagnosed with esophageal cancer, 16 with cancer of 
the gastric cardia, and 36 with high-grade dysplasia. In the entire cohort, incidence of esophageal or gastric 
cardia cancer or high-grade dysplasia combined was 0.22% per year (95% confidence interval [CI] = 0.19% to 
0.26%). SIM was found in 46.0% of patients. In patients with SIM, the combined incidence was 0.38% per year 
(95% CI = 0.31 to 0.46%). The risk of cancer was statistically significantly elevated in patients with vs without 
SIM at index biopsy (0.38% per year vs 0.07% per year; hazard ratio [HR] = 3.54, 95% CI = 2.09 to 6.00, P < .001), 
in men compared with women (0.28% per year vs 0.13% per year; HR = 2.11, 95% CI = 1.41 to 3.16, P < .001), 
and in patients with low-grade dysplasia compared with no dysplasia (1.40% per year vs 0.17% per year; HR = 
5.67, 95% CI = 3.77 to 8.53, P < .001).
 Conclusion We found the risk of malignant progression among patients with BE to be lower than previously reported, 
suggesting that currently recommended surveillance strategies may not be cost-effective.
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BE, that is, specialized intestinal metaplasia (SIM). Debate con-
tinues as to whether the definition of BE should include SIM, 
which is usually defined by the histological confirmation of goblet 
cells within the columnar mucosa (13). Lack of a consensus defini-
tion has led to differing recommendations for patient entry into 
endoscopic surveillance programs (6,7).
In a previous publication, we presented follow-up data until 
1999 on 2969 patients from this cohort (14) . The current study 
includes 5553 additional patients, better identifies and classifies 
relevant outcomes, and extends follow-up until December 2008.
Subjects and Methods
The Northern Ireland Barrett’s esophagus Register (NIBR) includes 
every adult identified with BE, defined as CLE, within Northern 
Ireland (population 1.7 million) between 1993 and 2005 and now 
includes 9334 patients. We constructed the register by examining 
all pathology reports from esophageal biopsies obtained by endos-
copy in Northern Ireland over this period, irrespective of the 
diagnosis made by the reporting pathologist. We examined the 
clinical summaries for the biopsies to exclude from our study 
the pathology report of any biopsy that was taken at the esophago
gastric junction. Pathology reports relating to all esophageal 
biopsies were examined further by applying a standardized set of 
rules that were drawn up in consultation with gastroenterologists 
and pathologists. Only those biopsies that were documented to 
CONTEXT AND CAVEATS
Prior Knowledge
Reports have varied regarding the risk of developing esophageal 
adenocarcinoma in patients with Barrett’s esophagus.
Study Design
Cancer risk among 8522 patients with Barrett’s esophagus, 
defined as columnar esophageal epithelium with or without spe-
cialized intestinal metaplasia (SIM), was examined using data 
from the Northern Ireland Barrett’s esophagus Register for 1993–
2005 matched with cancer registry records. Patients were fol-
lowed to the end of 2008 (mean follow-up = 7.0 years). Incidence 
of cancer or high-grade dysplasia of the esophagus or gastric 
cardia cancer was calculated as the number of events per 100 
person-years of follow-up.
Contribution
The incidence of cancer or high-grade dysplasia in this population-
based study was 0.22% per year; it was 0.38% per year among 
those with SIM at index biopsy. Cancer risk was higher among 
patients with SIM, patients with low-grade dysplasia, and male 
patients.
Implications
Risk of cancer among patients with Barrett’s esophagus was lower 
in this study than in previous studies, so current surveillance strat-
egies might not be optimal.
Limitations
Standardized biopsy protocols or pathological reporting were not 
used. Reasons for endoscopy and complete data on segment 
length were not available.
From the Editors
 
show CLE were included in the study. The date of the earliest 
(index) biopsy showing CLE was taken as the date of entry into the 
register. A statement in the clinical summary that Barrett’s mucosa 
was seen or suspected at endoscopy was used to further classify the 
biopsies as “macroscopic BE.” Details on the length of the Barrett’s 
mucosal region were also noted where available. Mucosal areas of 
columnar metaplasia that were of 3 cm or more in length were 
classified as long-segment Barrett’s esophagus (LSBE), and such 
areas that were less than 3 cm long were classified as short-
segment Barrett’s esophagus (SSBE). All esophageal biopsies with 
BE histology were further subdivided according to whether the 
pathologist specifically stated that SIM was present or absent in 
the biopsy specimen. If an esophageal biopsy showed evidence 
of malignancy, it was excluded from the study.
Patients were considered to have no dysplasia if the pathologist 
reported “no dysplasia”; low-grade dysplasia, if the pathologist 
reported the presence of “low-grade,” “mild,” “moderate,” or 
“indefinite”dysplasia; and high-grade dysplasia, if the pathologist 
reported “high-grade” or “severe” dysplasia. Otherwise, patients 
were classified as having unknown dysplasia status.
All 9334 patients in the NIBR were followed for deaths, inci-
dent esophageal and gastric cardia malignancies, and high-grade 
dysplasia of the esophagus until December 31, 2008. Patients who 
were diagnosed with high-grade dysplasia or cancer within 1 year 
of index biopsy were considered to have prevalent disease and were 
excluded from the analysis; patients with less than 12 months 
follow-up since their initial diagnosis of BE were also excluded. 
Patients with incident esophageal adenocarcinoma and histologi-
cally unspecified esophageal malignancies were identified by 
matching the cohort with the Northern Ireland Cancer Registry 
(NICR) database. Patients who developed other histological sub-
types of esophageal cancer, including squamous cell carcinomas, 
were excluded. The NICR records all cancers diagnosed within 
Northern Ireland. Incident gastric cardia adenocarcinomas and 
histologically unspecified carcinomas of the gastric cardia were 
identified within the cohort in a similar fashion. Classification of 
tumors of the esophagogastric junction is known to be difficult 
(15,16), so adenocarcinoma of the gastric cardia was included as an 
outcome because it is likely that these tumors in a patient with a 
history of BE are esophageal in origin. BE patients with high-
grade dysplasia were identified by examining all esophageal 
pathology reports from Northern Ireland for the period 1993–
2008. Patients were considered to have high-grade dysplasia if it 
was diagnosed twice within a 1-year period or in two subsequent 
biopsies, even if the duration between them was more than 1 year, 
or if high-grade dysplasia was present in a single biopsy and the 
duration of available follow-up after the development of high-
grade dysplasia was less than 1 year. High-grade dysplasia that 
occurred in squamous epithelium was not included as an outcome. 
Patients who were initially diagnosed with high-grade dysplasia 
but then diagnosed as having esophageal adenocarcinoma on sub-
sequent biopsy were classified as having esophageal adenocarci-
nomas for the purposes of analysis. Deaths were identified by 
matching with death files from the Northern Ireland Registrar 
General’s office using the patient’s surname, first name, and date 
of birth. Socioeconomic status of patients was estimated by 
deriving income deprivation quintiles from patient address data.
jnci.oxfordjournals.org   JNCI | Articles 1051
Statistical Methods
In this study, the primary outcomes of interest were diagnoses of 
esophageal cancer, cancer of the gastric cardia, or high-grade 
dys plasia of the esophagus that occurred at least 12 months after a 
patient’s first biopsy showed the presence of BE. Person-years of 
follow-up were calculated for each member of the cohort with 
censoring on the date of death, on the date on which cancer was 
diagnosed, on the date on which high-grade dysplasia was diag-
nosed if cancer did not occur subsequently, or at the end of fol-
low-up (December 31, 2008). Incidence of the primary outcomes 
was calculated as the number of events divided by the person-years 
of follow-up and was expressed as events per 100 person-years (% 
per year) of follow-up.
The data were analyzed for cancer outcomes and for the com-
bined outcome of cancer or high-grade dysplasia; the analysis was 
repeated for those with SIM at index biopsy. We examined inci-
dence of cancer or high-grade dysplasia according to factors that 
included age, sex, segment length, presence of SIM at index bi-
opsy, and low-grade dysplasia at index biopsy. We analyzed data 
from biopsies after the index biopsy to assess the risk of malignant 
progression in patients who developed low-grade dysplasia after 
their index biopsy. We also performed sensitivity analyses that 
included additional patients with at least 6 months of follow-up 
time and events occurring after 6 months. However, the analyses 
including patients with at least 6 months follow-up showed similar 
incidence rates to those seen in the main analysis (data not shown).
We used survival analysis to examine the risk of progression to 
cancer over time in BE patients. We used Cox proportional haz-
ards modeling to compare the incidence of cancer by variables 
including age group (<50, 50–59, 60–69, 70–79, or ≥80 years), sex 
(male or female), length of BE segment (long, short, or unknown), 
presence of SIM at index biopsy (present, absent, or unknown), 
presence of visible segment of BE (yes or unknown), and presence 
of low-grade dysplasia at index biopsy (present, absent, or 
unknown). All variables were treated as categorical for the Cox 
proportional hazards model and were adjusted for each other 
within the model. Kaplan–Meier curves were plotted for each var-
iable to examine the assumption of proportional hazards. Hazard 
ratios (HRs) and 95% confidence intervals (CI) were calculated. 
P values that were less than .05 were considered to be statistically 
significant. All P values were from two-sided tests. The x2 and 
independent samples t tests were used to compare demographic 
data between groups. All statistical analysis was conducted using 
SPSS version 15 (SPSS Inc, Chicago, IL).
Results
Patient Characteristics
A total of 9334 patients were diagnosed with CLE in Northern 
Ireland between 1993 and 2005 (Table 1). Of this cohort, 5437 
(58.2%) were men and 3897 (41.8%) were women, with a mean 
age of 60.9 years. Men were younger than women at the time 
of BE diagnosis (mean age = 58.6 vs 64 years; P < .001). Income 
deprivation quintiles as a marker of socioeconomic status were 
available for 83.5% of the NIBR cohort. Statistically significantly 
more BE patients were from the lowest socioeconomic group 
than the highest (18.2% vs 14.6%, P < .001). A total of 96 patients 
Table 1. Characteristics of patients in the Northern Ireland Barrett’s 
esophagus register
Characteristic No. (%), n = 9334
Sex
 Female 3897 (41.8)
 Male 5437 (58.2)
Mean age (SD, y) 60.9 (15.5)
Age group, y
 <50 2336 (25.0)
 50–59 1973 (21.1)
 60–69 2065 (22.1)
 70–79 1917 (20.5)
 ≥80 1043 (11.2)
Specialized intestinal metaplasia at index  
  biopsy
 Absent 3388 (36.3)
 Present 4307 (46.1)
 Unknown 1639 (17.6)
Dysplasia at index biopsy
 No dysplasia 8775 (94.0)
 Low-grade dysplasia 374 (4.0)
 High-grade dysplasia 96 (1.0)
Socioeconomic status (income deprivation  
  quintile)
 Most-deprived quintile 1701 (18.2)
 Quintile 2 1650 (17.7)
 Quintile 3 1552 (16.6)
 Quintile 4 1473 (15.8)
 Least-deprived quintile 1360 (14.6)
 Unknown 1598 (17.1)
were excluded from the analysis because they had high-grade dys-
plasia at baseline, and 189 additional patients were excluded 
from analysis because, having been diagnosed with high-grade 
dysplasia or cancer within 1 year of index biopsy, they were classi-
fied as having prevalent disease. Furthermore, 527 patients were 
excluded because they had less than 1 year of follow-up. This left 
8522 patients for analysis, who were followed for up to 16 years. 
Of these 8522 patients, 2840 (33.3%) were noted to have an endos-
copy with biopsy subsequent to the index biopsy. The average 
number of endoscopies with biopsies for the whole cohort was 1.8 
per person; 1538 patients (18%) had a total of three or more en-
doscopies with biopsies.
SIM was documented in almost half of the patients (3917 of 
8522: 46.0%), as judged from their index biopsies (Table 2). 
Patients with SIM were more likely to be men (59.1% vs 49.8%, 
P < .001) and older (mean age 62.0 vs 57.0 years, P < .001) than 
those whose biopsies showed no evidence of SIM (data not shown). 
For 3462 (40.6%) of the 8522 patients, the clinical summary 
recorded that Barrett’s mucosa was seen or suspected at endoscopy 
(Table 2). The length of the BE segment was poorly documented 
within the clinical summaries for most patients, with the majority 
(6894 of 8522; 81.0%) listed as unknown; 947 (11.1%) of 8522 of 
patients were recorded as having LSBE and 681 (8.0%) of 8522 as 
having SSBE. The majority of patients in the cohort (8128 of 
8522; 95.4%) did not have dysplasia at index biopsy.
The mean period of follow-up for the 8522 patients included 
for analysis was 7.0 years, and the total number of person-years of 
follow-up within the study period was 59 784. There were 79 
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patients diagnosed with esophageal cancer at least 12 months after 
diagnosis of CLE (62 with esophageal adenocarcinoma, one with 
esophageal adenosquamous carcinoma, and 16 with histologically 
unspecified carcinomas of the esophagus). Sixteen additional 
patients were diagnosed with adenocarcinoma of the gastric cardia, 
and 36 patients developed high-grade dysplasia during follow-up. 
The mean age at diagnosis was 63.3 years (SD = 11.8) for esopha-
geal adenocarcinoma and adenocarcinoma of the gastric cardia, 
and 59.8 years (SD = 12.1) for high-grade dysplasia.
Incidence of Cancers and Combined Events in BE
The incidence of cancers in the whole cohort was 0.16% per year 
(95% CI = 0.13% to 0.20% per year; Table 2). This estimate 
increased when the rate of the combined events (cancers or high-
grade dysplasia) was examined: 0.22% per year (95% CI = 0.19% 
to 0.26% per year).
Incidence of Cancers and Combined Events in Different 
Subgroups
We categorized the rates of cancers and combined events accord-
ing to sex, age category, SIM status, macroscopic BE, segment 
length, and presence of low-grade dysplasia (Table 2). Analysis by 
sex showed that men were statistically significantly more likely to 
progress to malignancy than women; the risk of combined cancer 
or high-grade dysplasia was 0.28% per year in men compared with 
0.13% per year in women (adjusted HR for combined events = 
2.11, 95% CI = 1.41 to 3.16, P < .001). The relationship between 
age and risk of neoplastic progression was complex. When initially 
examined as a continuous variable, age was statistically signifi-
cantly associated with the risk of neoplastic progression (adjusted 
HR = 1.02, 95% CI = 1.01 to 1.03, P < .05). However, on closer 
inspection of the data, risk of progression did not uniformly 
increase with age. To provide further insight into the relationship, 
categorical analysis was also conducted. When analyzed by age 
category, the highest risk of progression appeared in the 60- to 
69-year age category (0.33% per year), and the lowest risk in 
patients younger than 50 years (0.12% per year). The group of 
patients who were older than 80 years showed a low risk of pro-
gression, 0.17% per year, although this category had the shortest 
follow-up (4006 person-years). Incidence with age by sex is shown 
in graphical form (Figure 1). Statistical analysis did not reveal an 
interaction between incidence with age (categorical) and sex (P = 
.55). The incidence of combined events did not vary by socioeco-
nomic status (data not shown).
The incidence in patients with a visible BE segment at endos-
copy was 0.15% per year (95% CI = 0.11% to 0.21% per year) for 
cancer and 0.23% per year (95% CI = 0.17% to 0.30% per year) 
for combined events. No statistically significant difference was 
detected between this rate and that seen in patients with unknown 
visible segment status.
Presence of low-grade dysplasia at index biopsy was associated 
with the greatest risk of progression to cancer (combined events’ 
risk = 1.40% per year, 95% CI = 0.99% to 1.97% per year); 
patients with low-grade dysplasia were at much greater risk than 
those with no dysplasia at index biopsy (1.40% vs 0.17% per year, 
adjusted HR = 5.67, 95% CI = 3.77 to 8.53, P < .001). A similar 
risk of progression was seen among the 288 patients who were 
Figure 1. Incidence of combined cancer or high-grade dysplasia of 
the esophagus in patients with Barrett’s esophagus, by sex and age 
category.
classified as having no dysplasia at index biopsy but were diagnosed 
with low-grade dysplasia at subsequent biopsy (combined event’s 
risk = 1.37% per year, 95% CI = 0.99% to 1.90% per year).
A subset of 1990 patients with “well-defined” BE (both SIM 
and visible segment present) had a mean follow-up of 6.2 years and 
a total follow-up of 12 312 person-years. The incidence of com-
bined events in this group was 0.33% per year (95% CI = 0.24% 
to 0.45% per year). This incidence is not significantly different 
from the incidence seen in the SIM subgroup, although it is higher 
than the rate seen in the whole cohort.
Subgroup Analysis by SIM Status
The incidence of cancers in patients with SIM at index biopsy was 
0.27% per year (95% CI = 0.22% to 0.34% per year), and the 
incidence of combined events in this group was 0.38% per year 
(95% CI = 0.31% to 0.46% per year). Adjusting for other factors, 
the risk of cancer was statistically significantly higher in patients 
with SIM than in patients whose biopsies did not show SIM at first 
biopsy (0.38% vs 0.07% per year; HR = 3.54, 95% CI = 2.09 to 
6.00, P < .001; Table 2). Further examination of the 13 patients 
without index SIM who developed cancer or high-grade dysplasia 
determined that 10 of these patients had interval biopsies before 
developing cancer and that seven of the 10 biopsies showed SIM.
We next compared the risk of progression to cancer by SIM 
status at index biopsy (Table 3). The incidence rates of combined 
events were statistically significantly lower across most subgroups 
analyzed when we compared patients without SIM at index biopsy 
to those with SIM.
Rate of Progression to Cancer Over Time
The Kaplan–Meier plot of progression to cancer over time for the 
entire NIBR cohort (Figure 2) illustrates a uniform rate of pro-
gression to cancer. Risk of progression to cancer in the years 1–6 
(0.25% per year, 95% CI = 0.20% to 0.31% per year) following 
index biopsy was similar to that in the years 6–11 (0.27% per year, 
95% CI = 0.20% to 0.37% per year). No statistically significant 
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difference was seen for the years after the 11th year (0.28% per 
year, 95% CI = 0.14% to 0.58% per year).
Discussion
This study is one of the largest population-based studies to date to 
investigate the risk of esophageal malignancy in patients with BE. 
Previous work from the NIBR showed a low risk of progression to 
cancer in CLE patients with SIM (0.4% per year) and without SIM 
(0.26% per year) (14). Despite the inclusion of adenocarcinoma of 
the gastric cardia and high-grade dysplasia as outcomes, this larger 
study, which had much longer follow-up, shows a lower risk of 
progression and makes it possible to more accurately determine 
risk in subgroups and to estimate changes in risk of progression 
over time.
This study found that among all patients with CLE, the inci-
dence of cancer was 0.16% per year, and the incidence of com-
bined cancer or high-grade dysplasia was 0.22% per year. A recent 
study from the Netherlands reported an incidence of combined 
cancer or high-grade dysplasia of 0.58% per year in a large cohort 
of unselected BE patients (17). These incidence rates are lower 
than those in previously published studies that have reported risks of 
progression to cancer of up to 3% per year in other populations (11).
Reasons that previous studies may have overestimated the risk 
of cancer include smaller study size, shorter duration of follow-up, 
variable definition of BE used, inclusion of patients with early 
incident cancer, and inclusion of patients with high-grade dys-
plasia at baseline (11,12). As such, the low incidence of cancer in 
this study may in part be accounted for by the larger study size, the 
rigid exclusion of baseline high-grade dysplasia and early incident 
cancer, and the nature of an unselected non–referral-based cohort. 
The inclusion of patients with intestinal metaplasia from the 
esophagogastric junction could lead to an underestimate of the risk 
of cancer. Jung et al. (18) found that patients with intestinal meta-
plasia of this area are at a lower risk of cancer than those with BE. 
This study specifically excluded biopsies that were stated to have 
come from the esophagogastric junction; however, it is still pos-
sible that some biopsies were from this area.
Previous studies have used different definitions for the malig-
nancies that develop from BE. In this study, adenocarcinoma of 
the gastric cardia was included as an outcome because tumors of 
the esophagogastric junction are likely to be esophageal in origin 
in patients with a history of BE. Chandrasoma et al. (16) found that 
most adenocarcinomas of the gastric cardia were esophageal ade-
nocarcinomas if the esophagogastric junction was defined as the 
proximal limit of the gastric mucosa.
A change in risk of progression to esophageal cancer with age 
among BE patients has been reported in some studies (19,20) but 
not in others (21–23). Data from the NIBR showed that the rate of 
progression to cancer varied with age category, with peak cancer 
incidence in the 60- to 69-year age group, and a reduction in inci-
dence if BE was first diagnosed when patients were older than 70 
years. Possible reasons for this variation in cancer incidence by age 
group may include differences in the indication for the index en-
doscopy, lower malignant potential in BE that presents at later age, 
or differences in mortality rates between the age groups. Some 
patients who are diagnosed with BE at an older age may not sur-
vive long enough to develop BE-related cancer.
Differences in cancer risk between the sexes have also been 
variably reported (20,23,24). In our entire cohort, men were more 
Table 3. Comparison of combined outcomes (adenocarcinomas of the esophagus or gastric cardia or high-grade dysplasia) among 
Barrett’s esophagus patients with columnar lined epithelium of the esophagus (CLE) with or without specialized intestinal metaplasia 
(SIM)
Characteristic
CLE without SIM, incidence:  
% per year (95% Confidence Interval [CI])
CLE with SIM, incidence:  
% per year (95% CI) Hazard ratio (95% CI) P*
Sex
 Female 0.05 (0.02 to 0.11) 0.26 (0.18 to 0.38) 5.65 (2.18 to 14.68) <.001
 Male 0.10 (0.06 to 0.17) 0.45 (0.36 to 0.56) 4.63 (2.52 to 8.49) <.001
Age category, y
 <50 0.03 (0.01 to 0.10) 0.25 (0.15 to 0.41) 7.02 (2.05 to 24.09) .001
 50–59 0.10 (0.04 to 0.23) 0.37 (0.25 to 0.54) 3.78 (1.45 to 9.87) .002
 60–69 0.11 (0.05 to 0.26) 0.49 (0.35 to 0.68) 4.46 (1.75 to 11.35) .001
 70–79 0.08 (0.03 to 0.23) 0.43 (0.29 to 0.64) 5.45 (1.64 to 18.09) .001
 ≥80 0.08 (0.01 to 0.44) 0.29 (0.13 to 0.63) 3.39 (0.41 to 28.25) .135
Visible segment seen
 Unknown 0.07 (0.04 to 0.12) 0.41(0.32 to 0.52) 6.27 (3.31 to 11.87) <.001
 Yes 0.09 (0.04 to 0.20) 0.33 (0.24 to 0.45) 3.72 (1.58 to 8.77) .001
Segment length†
 Short 0.05 (0.01 to 0.28) 0.15 (0.05 to 0.44) 2.92 (0.31 to 28.76) .47
 Long 0.23 (0.08 to 0.67) 0.50 (0.34 to 0.74) 2.19 (0.66 to 7.29) .36
 Unknown 0.06 (0.03 to 0.10) 0.37 (0.30 to 0.46) 5.72 (3.18 to 10.28) <.01
Index dysplasia status
 No dysplasia 0.06 (0.04 to 0.10) 0.31 (0.25 to 0.38) 5.04 (2.86 to 8.89) <.001
 Low grade 0.91 (0.31 to 2.64) 1.45 (0.98 to 2.13) 1.53 (0.47 to 5.10) .75
 Unknown 0 0.33 (0.06 to 1.85) Not calculable NA
* P values were from two-sided tests, using Cox proportional hazards modeling to estimate hazard ratios.
† Segment length was categorized as short (<3cm), long (>3cm), or unknown.
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Figure 2. Kaplan–Meier plot showing the proportion of Barrett’s esophagus (BE) patients who developed esophageal or gastric cardia cancer or 
esophageal high-grade dysplasia relative to time from first diagnosis of BE. The asterisk denotes that individuals who developed cancer or high-
grade dysplasia in the first year after diagnosis of BE were presumed to have had prevalent disease and were excluded from the study. In this 
graph, 95% confidence intervals are shown at biennial intervals.
than twice as likely to develop high-grade dysplasia or cancer com-
pared with women. An apparent lag between women and men 
developing cancer is also seen in the NIBR cohort (Figure 1). The 
higher male to female ratio of patients diagnosed with esophageal 
adenocarcinoma may be explained by the finding that men de-
velop BE at younger ages compared with women (25). Women 
appear to develop BE up to 20 years later than men (26). This 
pattern, combined with the latent period between development of 
BE and progression to cancer, may mean that fewer women than 
men have BE for sufficiently long periods to develop esophageal 
adenocarcinoma.
It is generally believed that the risk of esophageal adenocarci-
noma among patients with BE is confined to patients with SIM 
(27–29). Findings from the current study largely support this pre-
mise, because the hazard ratio of combined events was over three 
times greater in those with SIM at index biopsy than in those with-
out SIM. However, patients with absence of SIM are not entirely 
without risk of esophageal adenocarcinoma. Among the 3179 
patients who did not have SIM in their index esophageal biopsies, 
four developed high-grade dysplasia and 13 developed cancers. 
When the data for those patients were examined further, 10 of the 
patients had had interval biopsies before developing cancer or 
high-grade dysplasia, of which seven showed SIM. Therefore, 
cancer that occurs in CLE without SIM may actually be occurring 
in SIM that was not diagnosed because of sampling error or pa-
thologist misclassification. Sampling error has been shown to be a 
major limitation in the diagnosis of BE (13). SIM may also have 
developed over time, so cancer risk in patients without SIM cannot 
be completely ignored. Misclassification of index SIM means that 
a small proportion of those that were classified as SIM-negative 
will have a higher risk of malignant progression than the rest. In 
this study, the hazard ratio for malignant progression comparing 
index SIM–positive patients with index SIM–negative patients may 
therefore be an underestimate. This finding also provides a reason 
to consider all patients with CLE, regardless of SIM status, for 
entry into surveillance, as is currently recommended by British 
guidelines. However, clinicians need to balance this consideration 
with the disadvantages of entering all patients in this lower-risk 
group into surveillance. Research into more accurate histological 
classification of index SIM status, or using the index biopsy for risk 
stratification, for example, through tissue biomarkers, may resolve 
this issue. This study demonstrates a very low incidence of cancer 
(0.06% per year) in patients who have columnar epithelium in 
their esophagus without SIM at index biopsy. The value of routine 
endoscopic surveillance must be questioned in these patients, on 
both clinical and economic grounds.
Considerable debate exists over the relationship between the 
length of Barrett’s segment and risk of cancer (30–33). Analysis of 
unadjusted data from the NIBR initially indicated that patients 
with LSBE have a statistically significantly higher risk of progres-
sion to cancer than patients with SSBE; however, no statistically 
significant difference was found following adjustment for other 
variables. The finding that BE length is not a statistically signifi-
cant determinant of cancer risk is in keeping with evidence from a 
systematic review (12); however, the results from the NIBR should 
be interpreted with caution because data regarding segment length 
were available for fewer than 20% of the patients in the cohort.
Patients in the NIBR cohort who had low-grade dysplasia had 
a higher risk of progression to cancer than those without dysplasia. 
Their risk for developing high-grade dysplasia or cancer was 1.4% 
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per year, with a hazard ratio 5.7 times that of patients who had BE 
but no dysplasia. A similar risk (1.28% per year) was seen in a study 
of 575 BE patients in California (34). Other studies (35–37) dem-
onstrated that about one quarter of patients with low-grade dys-
plasia progressed to cancer, however these studies were based on 
small numbers of patients (n = 20–34) and included cancers that 
occurred during the first 12 months after BE diagnosis.
It is clear that the cost-effectiveness of a BE surveillance pro-
gram is dependent on the incidence of cancer in the group under 
surveillance. The risk of malignancy and high-grade dysplasia that 
was seen among patients with SIM in this study (0.38% per year) 
is similar to the estimate used by Provenzale et al. (10) in their 
modeling of the cost-effectiveness of endoscopic surveillance in 
BE. They concluded that, with this risk of cancer, 5-year surveil-
lance was the only viable strategy, because endoscopic and surgical 
complications result in a lower gain in quality-adjusted life expec-
tancy with shorter surveillance intervals. Another study (9) that 
modeled surveillance from the perspective of the UK health-care 
system concluded that at a cancer risk equivalent to 0.5% per year, 
it costs less and results in a better quality of life to do no surveil-
lance than to do surveillance at any surveillance interval. A lower 
estimate of cancer incidence, such as the one that is identified in 
our study, would further reduce the cost-effectiveness of surveil-
lance in this model and would call the cost-effectiveness of the 
current surveillance program in the United Kingdom into 
question.
Surveillance of patients with a cancer risk of 1% per year or 
higher is possibly cost-effective (10,38–40). In the NIBR cohort, a 
cancer risk of this magnitude is limited to patients with low-grade 
dysplasia. According to our study, limiting surveillance to BE 
patients with low-grade dysplasia in their index biopsy would 
reduce the number of patients requiring surveillance by 95%, but 
importantly, only 24% of incident cancers or high-grade dysplasia 
occurred within this group.
A further consideration is that current surveillance protocols 
assume a constant risk of progression to cancer over time. To date, 
only one study (17) has reported on the relationship between the 
duration of BE and patients’ risk of progression to cancer. That 
study showed an increase in cancer risk with increased duration of 
BE. Results from the NIBR demonstrate a constant risk of pro-
gression to cancer over time, suggesting that patients require a 
uniform frequency and interval between endoscopies within any 
surveillance program.
Advantages of this study include the large study size and the 
avoidance of referral bias to tertiary care centers because everyone 
identified as having BE within a recognized geographic boundary 
was potentially included in the study. Identification of incident 
malignancies using a cancer registry that covers the identical 
geographic area has minimized loss to follow-up, which may be 
substantial in hospital-based surveillance cohorts (41). A further 
strength of the study is that endoscopic ablation of BE was not 
routinely undertaken in Northern Ireland during the study period, 
which minimizes alteration of the natural history of BE. Specifically 
excluding outcomes that were diagnosed within 12 months of the 
BE diagnosis minimized the capture of prevalent tumor data that 
would have falsely elevated the risk of progression to malignancy 
in BE.
There are some limitations with this study. It is a pragmatic 
study that utilizes routine UK National Health Service data, and 
our classification of BE is unlikely to be as robust as that of other 
studies that were undertaken in specialist referral centers, where 
specific esophageal biopsy protocols are used. However, this study 
reflects standard clinical practice, and its findings may be more 
widely applicable within standard health care. This study specifi-
cally excluded biopsies that were reported to be taken from the 
esophagogastric junction; however it is possible that some biopsies 
were taken from this junction. A recent study has shown that intes-
tinal metaplasia in this area has a substantially lower risk of pro-
gression to esophageal cancer than from BE found in the 
esophagus (18). Therefore, our study may underestimate the risk 
of malignant progression. There is the potential for loss of fol-
low-up of those patients who have migrated from Northern 
Ireland. However, data from the Northern Ireland Statistics and 
Research Agency (42) indicate that there is a low rate of emigration 
from Northern Ireland among people who are older than 60 years, 
at between 0.2% and 0.3% per year A further limitation is the 
availability of clinical information for individual biopsies such as 
the reason for endoscopy. The NIBR is a pathology-based register, 
and data from the clinical summary in pathology reports are not 
uniformly recorded. However, the majority of patients are likely to 
have been investigated due to symptoms because the index endos-
copy was used for creation of the NIBR database. Limited avail-
ability of clinical data has restricted the precision with which 
incidence of cancer or high-grade dysplasia can be calculated 
according to these factors.
In summary, this study has shown a lower incidence of cancer 
among patients with BE than what was previously reported. 
Current recommendations for surveillance are based on higher 
estimates of cancer risk among patients with BE than were seen in 
this study and therefore, they may not be justified. We eagerly 
await further research into tissue biomarkers, optical recognition 
of dysplasia, and nonsurgical therapies for dysplasia and neoplasia. 
Such research may enable targeted surveillance of those BE 
patients who are at greatest risk of neoplastic progression with the 
ultimate aim of reducing morbidity and mortality from esophageal 
adenocarcinoma.
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